{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.57","upperLimit":"29.17","value":"14.6"},{"groupId":"OG001","lowerLimit":"3.89","upperLimit":"31.66","value":"13.8"},{"groupId":"OG002","lowerLimit":"8.07","upperLimit":"29.80","value":"17.0"},{"groupId":"OG003","lowerLimit":"9.56","upperLimit":"23.07","value":"15.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"123"}],"units":"Participants"}],"description":"Percentage of participants who achieved biochemical control defined as GH \\<1μg/L and IGF-1 \\<ULN at week 36, by previous treatment and overall - last observation carried forward (LOCF)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).","id":"OG000","title":"Lanreotide 120 mg"},{"description":"Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .","id":"OG001","title":"Octreotide 30 mg"},{"description":"Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).","id":"OG002","title":"Octreotide 40 mg"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG003","title":"Pasireotide LAR Overall"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36 by Previous Treatment and Overall - LOCF","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}